Medical device company HistoSonics sold a majority stake to a group of investors, valuing it at $2.25 billion, the company announced Thursday.
Why it matters: HistoSonics — which was reportedly weighing an IPO in January — will continue to explore financing alternatives that keep the company private, CEO Mike Blue tells Axios Pro.
